One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study

Figures & data

Figure 1. Geometric mean titer of antibodies at various time points after the vaccination from day 0 through month 12. Error bars indicate 95% Confidence intervals (CI). The data of GMTs from day 0 to 56 have been showed in the initial study.²⁰

Figure 2. Accumulation curve of antibodies after vaccination at month 6 and 12. Figure A: Accumulation curve of antibodies to anti-F1 after vaccination in 15 and 30 groups at month 6 and 12. Figure B: Accumulation curve of antibodies to anti-rV after vaccination in 15 and 30 groups at month 6 and 12.

Table 1. Immunogenicity of antibodies to anti-F1 and anti-rV after vaccination at month 6 and 12.

	15 µg group	30 µg group	P-value
Antibody to anti-F1
Seroconversion rate at month 6	100.00%(119/119)	100.00%(118/118)	—
GMT (95% CI) at month 6	165.31(134.00-196.60)	270.33(219.50-321.20)	<0.0001
Seroconversion rate at month 12	99.16%(118/119)	100.00%(118/118)	1.0000
GMT (95% CI) at month 12	140.10(93.94-186.30)	198.80(152.30-245.20)	<0.0010
Antibody to anti-rV
Seroconversion rate at month 6	42.02%(50/119)	49.15%(58/118)	0.2701
GMT (95% CI) at month 6	452.50(325.80-579.20)	728.50(358.10-1099.00)	0.1656
Seroconversion rate at month 12	16.81%(20/119)	27.12%(32/118)	0.0551
GMT (95% CI) at month 12	225.60 (123.30-347.90)	323.50 (204.90-442.10)	0.0866

P: Group 15 µg compared with Group 30 µg at the same visit time.

^# P < 0.01,

* : Fisher's Exact Test.

Chu K, Hu J, Meng F, Li J, Luo L, Xu J, Yuan Z, Li Z, Chen W, Jiao L, et al. Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial. Human vaccines & immunotherapeutics 2016;12:2334–40. doi:10.1080/21645515.2016.1175261.

 PubMed Web of Science ®Google Scholar